Eyenovia Announces Conference Call and Webcast for First Quarter 2018 Financial Results
April 19, 2018 08:30 ET
|
Eyenovia, Inc.
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Announces Fourth Quarter and Full Year 2017 Financial Results
April 02, 2018 06:30 ET
|
Eyenovia, Inc.
NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Appoints Three Industry Veterans to Board of Directors
March 26, 2018 16:05 ET
|
Eyenovia, Inc.
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full Year 2017 Financial Results
March 19, 2018 08:30 ET
|
Eyenovia, Inc.
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its...
Eyenovia to Present at the 30th Annual ROTH Conference
February 27, 2018 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its...
Eyenovia Advances MicroPine for Myopia into Phase III Clinical Development and Appoints Stanford Professor Dr. Douglas Fredrick to its Scientific Advisory Board and Myopia Program Steering Committee
February 21, 2018 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its...
Eyenovia Announces Closing of $27.3 Million Initial Public Offering
January 29, 2018 16:05 ET
|
Eyenovia, Inc.
NEW YORK, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its...
Eyenovia Announces Pricing of Initial Public Offering
January 25, 2018 06:30 ET
|
Eyenovia, Inc.
NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print...
Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of micro-formulation over conventional eyedroppers and addition of Scientific Advisory Board members
November 28, 2016 15:46 ET
|
Eyenovia, Inc
Eyenovia’s study shows that conventional ophthalmic eye drops significantly overdose the eye and that equivalent, or greater, pharmacodynamic effect can be achieved with 80% less ocular exposure...